SOUTH SAINT PAUL, MN – (July 2, 2020) – Veterinary Hospitals Association (VHA), the leading association for veterinary practices in the Midwest, has reached a new partnership agreement with Parnell Living Science.
Parnell is a fully integrated pharmaceutical company dedicated to finding animal health solutions that matter. For over 50 years, Parnell has remained committed to the continued development of innovative products at the highest standard. Their focus is on combating the signs of arthritis with their cornerstone product, Glyde™ Mobility Chews.
“Parnell’s dedication to the veterinary industry is unparalleled,” explains Jeff Benson, Executive Director of VHA. “The superior products Parnell currently offers, and what they will have in the near future, provides our veterinary clinic members exciting ways to treat and manage their patient’s mobility health.”
“We are excited to partner with the visionary veterinary group of VHA,” said David Snapp, Senior Vice President & General Manager, US Operations for Parnell Living Science. “Working together to help our pets live a more active lifestyle with improved mobility is a passion for us all.”
Osteoarthritis (OA), or arthritis in dogs, is a painful joint disease occurring in 80% of dogs over age 8. Surprisingly, 20% of dogs will show signs of arthritis as early as age 1. Just as in humans, there is no cure for arthritis. Parnell’s Glyde Mobility Chews is a proven formula with the key ingredients working together to promote joint health and cartilage development. Glyde’s heart-shaped chews have glucosamine and chondroitin and also the power of green-lipped mussel (GLM) to help combat the illness.
As part of this agreement, VHA will stock and distribute Parnell companion animal products through their warehouse and members will have access to additional rebates from Parnell.
About Veterinary Hospitals Association
Veterinary Hospitals Association (VHA) was established in 1984 and is a not-for-profit association dedicated to supporting veterinary professionals and practices by offering solutions that enable them to grow, learn, and succeed. VHA currently serves over 420 member veterinary practices in Minnesota, Wisconsin, and North Dakota. Follow VHA on Facebook, Instagram, Twitter, and LinkedIn.
Parnell (OTC: PARNF) is a fully integrated pharmaceutical company focused on developing, manufacturing, and commercializing innovative animal and human health solutions. Parnell’s companion animal business is centered on canine osteoarthritis, where it manufactures and markets its proprietary brands Glyde in the USA, Australia, and New Zealand and Zydax in Australia and New Zealand. Parnell is a technology and clinical science leader in dairy reproduction, marketing its proprietary brands estroPLAN and GONAbreed via its dedicated sales force and digital technology mySYNCH in the USA and Australia-New Zealand, and via distributors in other markets. Parnell has a rapidly growing contract manufacturing business supplying industry majors with specialized sterile injectable products. Recently, Parnell leveraged its novel intellectual property position in the Pentosan Polysulfate drug class to address the human market through a new contract with a major global human health company. For more information on the company and its products, please visit www.parnell.com.
Veterinary Hospitals Association
Ph: (507) 360-6929